In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HITF (Healthcare Industries Task Force): the end of a new beginning for UK medical technology

This article was originally published in Clinica

Executive Summary

It is impossible in a brief summary to do justice to a strategy that seeks to re-steer and energise the £6bn ($11.2bn) machine that is the UK's medical technology industry. But last week's publication of the HITF report is actually just the end of the beginning - the nuts and bolts of a nine-part system designed by around 200 people over the last year to improve the machine's performance. That design is now ready to be engineered into the current R&D, manufacturing, marketing, healthcare delivery and regulatory systems, reports Bernard Murphy

You may also be interested in...



COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs and Tests

Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.

'Hunker Down, Expect The Worst And Hope For The Best:' Investment Analyst Advises Medtech Businesses To Cut Costs

Maxim Jacobs, managing partner at Edison Investment Research urges medtech companies to be financially prudent as the COVID-19 pandemic worsens. Cancellations of routine surgeries are creating a huge strain on device businesses which could continue for months.

COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs and Tests

Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.

Topics

UsernamePublicRestriction

Register

MT060270

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel